India's healthcare landscape will change as semaglutide patents expire in 2026, allowing over 50 generic versions to enter the market and improve access for diabetes and obesity treatment.

Rendering a drug effective or ineffective in a flash at the appropriate location—this is the focus of research in photopharmacology. The goal is to develop drugs that can be switched on and off with ...

Novo Nordisk's reports to the FDA spiked shortly after an inspection found the Ozempic producer ignored reports of deaths and potential side effects.

March 11 (Reuters) - The U.S. Food and Drug Administration said on Wednesday it has introduced a unified platform designed to ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster ...

Inside a diseased cell, the genes are in chaos. Some are receiving signals to overproduce a protein. Others are reducing ...

The FDA issued a warning letter to Novo Nordisk, the Danish drugmaker behind the diabetes and weight-loss medications Ozempic and Wegovy, over unreported potential side effects.

Officials wrote that Novo Nordisk had failed to failed to report ‘serious and unexpected’ adverse drug experiences ...

The FDA issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side ...

FDA launches new AI-powered system to track drug and vaccine side effects in real time, replacing outdated databases and saving $120 million annually.